🚨 Balding Breakthrough? New Oral Minoxidil Drug VDPHL01 Sends Veradermics Stock Soaring 50%

Muthu boy no scared of going bald anymore 😎

Recently, a new hair loss treatment called VDPHL01 successfully passed Phase 2 clinical trials, and many people are now eagerly waiting for it to hit the market. Its parent company, $Veradermics, Inc.(MANE)$  Veradermics saw its stock surge nearly 50%.

What’s interesting is that the main ingredient in VDPHL01 is actually Minoxidil.

Although there are already many Minoxidil hair growth solutions on the market, there has never been an FDA-approved oral Minoxidil specifically for treating hair loss. Current oral versions like Loniten were originally designed for high blood pressure. While some hair loss patients use them off-label, they can cause side effects like low blood pressure and dizziness, and off-label use also comes with less legal and medical protection if problems occur.

VDPHL01 is different because it uses an extended-release (ER) system that slowly releases Minoxidil into the body. This helps keep blood levels more stable and may reduce side effects such as heart palpitations and dizziness.

So while this isn’t exactly a brand-new drug, it combines an improved drug delivery system with FDA-targeted approval for hair loss treatment — making it something many patients are hopeful about.

@TigerClub  @TigerObserver  @TigerStars  @Daily_Discussion  @TigerPM